Alnea Chosen as Tradename for Watson’s Hormone Replacement Patch
This article was originally published in Pharmaceutical Approvals Monthly
Watson plans to use the name Alnea for its combination estradiol/progestin transdermal patch for treatment of vasomotor symptoms in postmenopausal women with an intact uterus. The firm submitted the names Estrapro, Alnea-SQ, Alnea-CC and Alneta SQ to the Patent and Trademark Office for a transdermal hormone replacement patch.
You may also be interested in...
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
The paradoxical finding that Dendreon's cancer immunotherapeutic Provenge (sipuleucel-T) improved overall survival in men with metastatic castration-resistant prostate cancer but did not appear to slow the progression of the disease is raising questions about the future of clinical development for the burgeoning class